StockData

BioCryst Pharmaceuticals vs Kiniksa Pharmaceuticals International

BCRX and KNSA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BCRX and KNSA compare

Kiniksa Pharmaceuticals International is the larger company, worth 7.8 times as much as BioCryst Pharmaceuticals ($14.9B against $1.9B).

BioCryst Pharmaceuticals grew revenue faster over the last twelve months (68.7% versus 58.2% for Kiniksa Pharmaceuticals International).

Kiniksa Pharmaceuticals International keeps more of each dollar of sales as profit, with a net margin of 11.6% compared with −40.9% at BioCryst Pharmaceuticals.

Kiniksa Pharmaceuticals International scores higher on the StockData Score (14 against 9 for BioCryst Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBCRXKNSA
Size and price
Market cap$1.9B$14.9B
Share price$7.50$95.11
Change, 1 year5.9%136%
Change, 5 years−39.9%716%
Beta (5Y)0.580.15
Employees435366
StockData Score
Total score914 (better)
Valuation score1 (better)0
Growth score44
Performance score24 (better)
Health score26 (better)
Dividend score00
Valuation
P/E–73.2×
P/S2.0× (better)15.8×
P/B–21.0×
EV/EBITDA–109×
P/FCF5.1× (better)75.8×
FCF yield19.5% (better)1.3%
Fair value–$16.72
Margin of safety–−469%
Growth
Revenue growth (TTM)68.7% (better)58.2%
Revenue growth, 5Y average118%–
Net income growth (TTM)–205%
EPS growth (TTM)–189%
Profitability
Gross margin97.8% (better)90.2%
Operating margin−33.3%13.8% (better)
Net margin−40.9%11.6% (better)
FCF margin39.7% (better)20.8%
Return on equity–17.6%
Return on invested capital–60.2%
Financial health
Debt / equity–0.00
Interest coverage−4.2×–
Current ratio2.323.91 (better)
Altman Z-score−3.8334.40 (better)
Piotroski F-score78 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions103%29.9%
Held by insiders1.9%5.1%
Insider net buying, 12 months−$4.1M (better)−$122M
Short interest, % of float11.0%2.9%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.